Tracers / [177Lu]Lu-LW02060
[177Lu]Lu-LW02060
Also written as [Lu-177]Lu-LW02060
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated bombesin(6-14) peptide analog (GRPR agonist)
- Target / mechanism
- Gastrin-releasing peptide receptor (GRPR) PMID 40006047
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ga68-lw02060/">ga68-lw02060</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | custom manifold | HPLC+SPE | 36–64% yes | >97% | LW02060 (DOTA-conjugated peptide) | 40006047 2025 Pharmaceuticals (Basel) 177LuCl3 (994–2240 MBq) was added into a 4 mL glass vial preloaded with 0.7 mL of NaOAc buffer (0.1 M, pH 4.5) and 10 μL precursor solution (1 mM) and incubated at 95 °C for 15 min with a heating block. — 177Lu-labeled LW02060 and LW02080 were obtained in 36–64% decay-corrected radiochemical yields with >125 GBq/µmol molar activity and >97% radiochemical purity |
Need this precursor?We can point you to suppliers for [177Lu]Lu-LW02060, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40006047. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40006047: 'LW02060 and LW02080 were synthesized on solid phase using Fmoc chemistry'.